As per MRFR analysis, the South Korea Diabetic Retinopathy Market Size was estimated at 137.92 (USD Million) in 2023. The South Korea Diabetic Retinopathy Market is expected to grow from 144.8 (USD Million) in 2024 to 482 (USD Million) by 2035. The South Korea Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 11.553% during the forecast period (2025 - 2035).
The rising prevalence of diabetes in the population, which has increased dramatically in recent years due to changes in lifestyle and an aging population, is driving notable developments in the diabetic retinopathy market in South Korea.
Healthcare providers are putting more of an emphasis on creating cutting-edge diagnostic technologies like optical coherence tomography and retinal imaging as a result of the South Korean government's desire to establish early detection and treatment programs.
This focus on technology is improving detection accuracy and increasing patient awareness of diabetic retinopathy, which is encouraging more people to get frequent eye exams. As telemedicine becomes increasingly ingrained in healthcare procedures, opportunities in this sector are also growing.
Patients can obtain timely care thanks to the convenience of remote monitoring and consultations, particularly in areas with limited access to specialised services. Furthermore, development possibilities are further stimulated by pharmaceutical companies' active engagement in developing novel medicines, such as anti-VEGF injections.
There is a lot of opportunity to investigate cutting-edge therapy approaches that can enhance patient outcomes because the government funds research projects and promotes collaborations between academic institutions and business.
In South Korea, patient-centered care models are becoming more popular, according to recent trends. In order to effectively manage chronic illnesses like diabetes and its consequences, this method incorporates individualised treatment programs that take into account each patient's needs and preferences.
Additionally, patient and healthcare provider education programs are becoming increasingly common, which helps lower the prevalence of diabetic retinopathy by promoting lifestyle changes and preventive measures.
All things considered, the South Korean market for diabetic retinopathy is developing quickly, marked by chances for collaboration, technical breakthroughs, and a move towards patient treatment that is holistic.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising prevalence of diabetes is one of the most significant drivers for the South Korea Diabetic Retinopathy Market. According to the Korea Centers for Disease Control and Prevention, the number of adults aged 30 and above diagnosed with diabetes has increased by approximately 12% in the past five years, translating to around 6 million individuals currently living with the condition.
This growth in diabetes patients directly correlates with higher incidences of diabetic retinopathy, as studies indicate that about 30% of individuals with diabetes may develop this eye condition.
Additionally, the South Korean government has initiated several health campaigns aimed at early detection and management of diabetes, which further boosts the demand for screening and treatment solutions in the diabetic retinopathy sector.
By prioritizing preventive healthcare and meeting the growing needs of this demographic, the South Korea Diabetic Retinopathy Market is poised for substantial growth in the upcoming years.
Technological advancements in diagnostic methods are significantly contributing to the expansion of the South Korea Diabetic Retinopathy Market. Innovations such as Optical Coherence Tomography (OCT) and smartphone-based retinal imaging have enhanced the ability to diagnose diabetic retinopathy at earlier stages.
For instance, a recent initiative in South Korea has involved the integration of Artificial Intelligence (AI) in retinal image analysis, improving accuracy rates by over 20% compared to traditional methods.
Notably, the Ministry of Health and Welfare is promoting the adoption of these advanced technologies, leading to a surge in the market as more healthcare facilities invest in state-of-the-art diagnostic equipment for timely and effective screening.
The South Korean government is making significant investments in eye health and diabetic retinopathy prevention, which serves as a major driver for the market. Recent policy changes have resulted in the allocation of a multimillion-dollar budget aimed at improving eye disease management and prevention strategies.
The government aims to decrease the incidence of diabetic retinopathy through extensive screening programs and public awareness campaigns focused on diabetes control.
These initiatives not only support existing healthcare infrastructure but also encourage research and development within the market. Organizations such as the Korean Ophthalmological Society are actively collaborating with the government to enhance treatment accessibility, ultimately bolstering the South Korea Diabetic Retinopathy Market.
The Type segment of the South Korea Diabetic Retinopathy Market primarily encompasses Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR), each displaying its own characteristics and significance within the overall landscape of diabetic eye diseases.
NPDR is typically the early stage of diabetic retinopathy, characterized by microaneurysms and retinal hemorrhages. It represents a considerable portion of the diabetic retinopathy patient population in South Korea, making awareness and early diagnosis crucial in preventing progression to more severe stages.
This underlines the importance of regular eye examinations, especially as the prevalence of diabetes continues to increase in the country. South Korea's growing aging population further enhances the significance of monitoring NPDR, as older adults are at a higher risk for developing diabetes and its corresponding ocular complications.
On the other hand, PDR is more advanced and poses a higher risk of vision loss. In this stage, new blood vessels grow abnormally on the retina, which can lead to further complications such as vitreous hemorrhage and retinal detachment.
Given that PDR can cause severe visual impairment, health authorities in South Korea are increasingly focusing on both treatment and prevention strategies tailored to manage this critical segment effectively. The rise in diabetes prevalence and advancements in screening technology are boosting efforts to diagnose both NPDR and PDR at earlier stages, leading to timely intervention.
The market's growth is likely driven by innovations in therapy options and an increased emphasis on patient education regarding diabetes management and eye health. Health campaigns promoting awareness of diabetic retinopathy could lead to improved treatment outcomes, significantly benefiting individuals affected by NPDR and PDR.
Moreover, the shifting dynamics of healthcare in South Korea, including the integration of telemedicine and enhanced access to ophthalmological services, position these segments for meaningful engagement and improvement in patient care and, ultimately, market growth.
In summary, the Type segment's characteristics and challenges reflect the broader trends of a healthcare system increasingly concerned with outcomes related to diabetes and its complications in the context of the South Korean healthcare landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the South Korea Diabetic Retinopathy Market plays a pivotal role in addressing the increasing prevalence of this condition among the population. Pharmacological therapies, which are designed to manage diabetic retinopathy effectively, focus on utilizing advanced medications that can slow disease progression and improve patient outcomes.
Laser treatment remains a vital option due to its effectiveness in targeting specific areas of the retina, significantly reducing vision loss risks. Additionally, surgical interventions are critical as they offer solutions for advanced cases, aiming to restore vision and improve quality of life.
Given the rising incidence of diabetes in South Korea, the demand for these treatments is expected to grow. The South Korean government has initiated various health programs to enhance awareness and accessibility of diabetic retinopathy treatments, thus encouraging early detection and intervention.
The ongoing Research and Development efforts in the pharmaceutical and medical device sectors also present considerable opportunities for innovation in treatment methodologies, ensuring that the South Korea Diabetic Retinopathy Market remains a dynamic and essential component of the healthcare landscape.
The South Korea Diabetic Retinopathy Market exhibits significant growth driven by various End-users, predominantly Hospitals and Clinics, Ophthalmology Centers, and Research Institutes. Hospitals and Clinics play a crucial role in diagnosing and treating diabetic retinopathy, accounting for a substantial share of patient care owing to their comprehensive facilities and specialist services.
Ophthalmology Centers are vital as they specialize in eye health, providing advanced diagnostic and treatment options tailored to diabetic retinopathy, which enhances patient outcomes and increases access to cutting-edge therapies.
Research Institutes contribute significantly by driving innovation through studies focused on new treatments and technologies, augmenting the overall understanding of diabetic retinopathy.
The increasing incidence of diabetes in South Korea underscores a growing necessity for effective screening and management of diabetic retinopathy, and as the population ages, demand for specialized care from these segments is anticipated to rise.
Furthermore, advancements in technology and an increase in healthcare expenditure are also pivotal growth drivers within this market, facilitating better treatment modalities.
The segmentation of the South Korea Diabetic Retinopathy Market reflects the dynamic approach to managing this chronic condition, thereby addressing the unique needs of patients across varying healthcare settings. Many healthcare stakeholders are collaborating to enhance patient education and streamline referral processes, ensuring comprehensive care for those affected by diabetic retinopathy.
The South Korea Diabetic Retinopathy Market is characterized by a competitive landscape that is shaped by advancements in clinical research, technology, and an increasing prevalence of diabetes within the region.
As the understanding of diabetic retinopathy grows, so too does the emphasis on innovative treatments and diagnostic tools. Key players in the market are focusing on enhancing their offerings, which include a blend of pharmaceutical interventions, surgical options, and advanced imaging techniques.
Competitive dynamics are influenced not only by the leading healthcare facilities and pharmaceutical companies but also by the collaborative efforts involving researchers, specialists, and technology developers.
This collaborative ecosystem is vital for addressing the challenges presented by diabetic retinopathy, which requires a multifaceted approach involving early detection and effective treatment methods.
Asan Medical Center is recognized as a leading institution in the South Korean healthcare landscape, especially in the context of diabetic retinopathy. The center boasts a strong reputation for its comprehensive ophthalmology services and a specialized team dedicated to the diagnosis and management of diabetic eye diseases.
Its state-of-the-art facilities enable the application of advanced diagnostic tools and treatment modalities, allowing the center to provide cutting-edge care to patients suffering from diabetic retinopathy.
The distinguished reputation of Asan Medical Center is enhanced by its commitment to continuous research and development in the field, positioning it as a central player in improving patient outcomes related to diabetic retinopathy across South Korea.
Seoul National University Hospital plays a pivotal role in the South Korea Diabetic Retinopathy Market, characterized by its integration of research, education, and patient care. The hospital is renowned for its skilled professionals who specialize in various aspects of ophthalmology, particularly in treating diabetic retinopathy.
Its extensive range of key services includes advanced imaging technologies and therapeutic options such as laser treatments and injections for managing diabetic macular edema. The market presence of Seoul National University Hospital is distinguished by its unwavering dedication to high-quality patient care and the development of innovative treatment techniques.
In recent years, the hospital has engaged in strategic collaborations and partnerships to bolster its research capabilities, paving the way for advancements in clinical practice. Its focus on education and training ensures that the next generation of ophthalmologists is well-equipped to tackle the challenges of diabetic retinopathy, further solidifying its position in this critical area of healthcare within South Korea.
Recent developments in the South Korea Diabetic Retinopathy Market have shown significant advancements and increased attention from various healthcare institutions and organizations. Notably, Asan Medical Center and Seoul National University Hospital have been at the forefront of pioneering Research and Development initiatives aimed at improving treatment outcomes for diabetic retinopathy.
Moreover, significant growth has been reported for LG Life Science as they expand their product range related to eye care, specifically targeting patients with this condition. In the sphere of mergers and acquisitions, there have been no widely reported transactions involving the primary companies in the diabetic retinopathy segment within the last few months.
However, a continual emphasis on collaborative efforts between institutions like Gangnam Severance Hospital and Korea Institute of Ophthalmic Research suggests potential future alignments aimed at enhancing patient care and treatment modalities.
Furthermore, market valuations for major players such as Samsung Medical Center and Pusan National University Hospital have seen upward trends, positively impacting the competitive landscape within South Korea.
Over the last couple of years, hospitals have been actively integrating advanced diagnostic tools, with significant implementations noted in early 2021. This surge in innovation and institutional collaboration highlights a focused effort towards battling diabetic retinopathy effectively within South Korea.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 137.92(USD Million) |
| MARKET SIZE 2024 | 144.8(USD Million) |
| MARKET SIZE 2035 | 482.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.553% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Asan Medical Center, Seoul National University Hospital, Korea University Medical Center, Hallym University Medical Center, Chonnam National University Hospital, Gangnam Severance Hospital, Korea Institute of Ophthalmic Research, LG Life Science, Bucheon St. Mary's Hospital, Pusan National University Hospital, Hana Medical Center, Yonsei University Health System, Inje University Haeundae Paik Hospital, National Health Insurance Service, Samsung Medical Center |
| SEGMENTS COVERED | Type, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Increasing diabetic population awareness, Advanced diagnostic technology integration, Expanded telemedicine services utilization, Growing investment in R&D, Enhanced patient education programs |
| KEY MARKET DYNAMICS | rising diabetes prevalence, increasing elderly population, advancements in diagnostic technologies, growing awareness and education, improving healthcare infrastructure |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The South Korea Diabetic Retinopathy Market is expected to be valued at approximately 144.8 million USD in 2024.
By 2035, the market is projected to reach around 482.0 million USD.
The expected CAGR for the South Korea Diabetic Retinopathy Market from 2025 to 2035 is 11.553%.
Non-Proliferative Diabetic Retinopathy (NPDR) is expected to be valued at approximately 230.0 million USD by 2035.
Proliferative Diabetic Retinopathy (PDR) is expected to be valued at around 252.0 million USD by 2035.
Key players in the market include Asan Medical Center, Seoul National University Hospital, and LG Life Science among others.
In 2024, the Proliferative Diabetic Retinopathy (PDR) segment is expected to dominate with a valuation of 74.8 million USD.
The growth drivers include an increasing prevalence of diabetes and advancements in ophthalmic technologies.
Challenges include limited awareness and access to treatment options among the population.
Current global developments can affect market dynamics, particularly in technology advancements and healthcare infrastructure investment.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
